On Apr. 6, 2020, IGEA Pharma announced that it was starting to supply of a COVID-19 antibody test following an agreement signed with a PRC independent SARS-CoV-2 IgM/IgG test developer and manufacturer. According to terms, IGEA has ensured the exclusivity of the test under certain volume-based conditions for the U.S. States New York, California, and Louisiana, severely affected by the pandemic outbreak.